This article introduces Anapharm Bioanalytics, a company that possesses a team with extensive experience and a lab equipped with cutting-edge technology. We investigate and summarize the characteristics and strengths of the non-clinical studies they handle, as well as past case examples.
Anapharm Bioanalytics is equipped with advanced instruments, including LC-MS/MS.Provides a wide range of biological sample analyses from low molecular weight to high molecular weight.With over 30 years of experience, the company offers one-stop solutions from preclinical studies to Phase 3 and bioequivalence trials. They also have strengths in complex analyses, such as high-sensitivity assays below the picogram level.Technical expertise with numerous verified methodsWe offer
At Anapharm Bioanalytics, where we place a very high importance on quality,Conduct studies in compliance with GLP (Good Laboratory Practice) and GCP (Good Clinical Practice).The company's Quality Assurance Unit is led by a director with extensive industry experience, ensuring the quality of research data through strict adherence to guidelines, continuous monitoring, process improvement, and staff training.
Anapharm Bioanalytics champions a "customer-first" philosophy.We value transparent and effective communication.is a feature. Each project is assigned a dedicated Study Director. We provide prompt support and regular progress reports, meeting customer requirements throughout each project.
Anapharm Bioanalytics isAnalytical CRO specializing in biological sample analysisTherefore, we do not sell or provide specific animal disease models. We support non-clinical development by directly analyzing biological samples such as blood received from clients in our own laboratories.
Anapharm Bioanalytics isA long track record is a distinguishing feature.This can be said. Although specific compound names are not disclosed due to sponsor confidentiality, they have a wealth of experience and a proven track record of successfully conducting non-clinical TK (toxicokinetics) studies for novel small and large molecule pharmaceuticals and developing and validating molecular methods for biomarker measurement for over 20 years since their establishment.
| Address | Encuny 22, 2nd floor, 08038 Barcelona, Spain |
|---|---|
| Tel | +34 93 223 86 36 |
| Website | https://www.anapharmbioanalytics.com/ |
In non-clinical development, the choice of contract research organization shapes the quality of the data and the time it takes to reach the next decision. Below, three CROs are introduced by the type of study they support: pharmacology (efficacy) studies, safety studies, and pharmacokinetic (PK/PD) studies. Each summary describes the services the company offers so that you can match a provider to your target and development objective.
SMC Laboratories is a specialized non-clinical CRO focused on in vivo pharmacology and efficacy studies using disease-relevant animal models, particularly in fibrosis, inflammation, metabolic diseases, and oncology.
SMC Laboratories offers models covering the liver, lung, kidney, intestine, and oncology. Its portfolio includes the proprietary STAM™ model for MASH, fibrosis, and hepatocellular carcinoma.
Study plans are developed around the target biology, mechanism of action, disease stage, and development objective. Pharmacological endpoints can be combined with histopathology, biomarkers, and disease-specific readouts.
With experience from more than 1,000 studies for clients in 30 countries, SMC Laboratories supports programs from target validation and candidate selection through in vivo proof-of-concept studies.
Charles River provides non-clinical toxicology and safety assessment services for programs ranging from exploratory safety studies to IND-enabling development.
Services include single- and repeat-dose toxicology, dose-range finding, and general toxicology studies across multiple species and administration routes.
Charles River supports both non-GLP and GLP studies, allowing sponsors to progress from early safety characterization to studies intended for regulatory submissions.
Toxicology studies can be integrated with toxicokinetics, clinical pathology, histopathology, and safety pharmacology to support interpretation and IND-enabling safety packages.
Inotiv provides integrated PK/PD, DMPK, and bioanalytical services to characterize drug exposure and its relationship with pharmacological response.
PK studies characterize exposure, half-life, clearance, and other pharmacokinetic parameters needed to understand how a candidate behaves in the selected model.
Pharmacokinetic data can be combined with pharmacodynamic endpoints and bioanalysis to evaluate the relationship between drug exposure and pharmacological response.
Integrated DMPK, pharmacology, and safety information supports candidate comparison, dose selection, dosing-frequency optimization, and decisions about subsequent preclinical development.